Nasdaq
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Nasdaq in real time with a live news feed covering Nasdaq stock news, official press releases, company announcements, and an archive of historical Nasdaq news. ...more
Loading news...
Loading more...
8:30 AM | Thursday | Oct 8, 2026
Sign in to download news snippet
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
Read full articleNo data available for this time period.
Change the time range to see results.
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
Read full article
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
Read full article
Amendment removes holder's optional redemption right on Series C Preferred Stock and supports the Company's plan to regain compliance with Nasdaq's listing requirements Amendment removes holder's optional redemption right on Series C Preferred Stock and supports the Company's plan to regain compliance with Nasdaq's listing requirements
Read full article
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for September 2026, as well as quarterly volumes, estimated revenue capture, number of listings, and index statistics for the quarter ended September 30, 2026, on its Investor Relations website.
Read full article
SALT LAKE CITY, Oct. 07, 2026 (GLOBE NEWSWIRE) -- FireFly Robotics, Inc. ("FireFly Robotics" or the "Company") today announced it has publicly filed a registration statement on Form S-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed public direct listing of its common stock.
FireFly Robotics has applied to list its common stock on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “FFLY”.
BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.
com) at 855-576-4847. There is no cost or financial obligation to you.
Key highlights Rezolve Ai presents its strategy, growth drivers and full agentic commerce stack to investors today at Nasdaq MarketSite, with live product demonstrations; investors can register here to join online. Rezolve Ai's US AI Visibility Study 2026 finds that 97 of America's 100 largest retailers publish no way for an AI agent to check out.
Read full article
Anderson steps into the role from inside the company, having chaired ONAR's Audit Committee since August 2025; director Howard D. Palefsky assumes the Audit Committee chair; appointment follows the completion days earlier of the largest acquisition in Company history and its up to $15 million financing Anderson steps into the role from inside the company, having chaired ONAR's Audit Committee since August 2025; director Howard D. Palefsky assumes the Audit Committee chair; appointment follows the completion days earlier of the largest acquisition in Company history and its up to $15 million financing
Read full article
Nasdaq confirms the Company has satisfied the condition in the September 9, 2026 Hearings Panel decision; common stock continues to trade on the Nasdaq Capital Market under the symbol CYCU, subject to a Discretionary Panel Monitor through October 1, 2027 Nasdaq confirms the Company has satisfied the condition in the September 9, 2026 Hearings Panel decision; common stock continues to trade on the Nasdaq Capital Market under the symbol CYCU, subject to a Discretionary Panel Monitor through October 1, 2027
Read full article
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026.
PHILADELPHIA, Oct. 1, 2026 /PRNewswire/ -- Aapryl, an institutional analytics platform for investment manager evaluation, today announced a data relationship with NasdaqeVestment. Mutual subscribers can now view the NasdaqeVestment-sourced manager products covered by their subscription within Aapryl and analyze them using Aapryl's skill attribution, factor, and scoring analytics.
Read full article
No data available for this time period.
Change the time range to see results.